Multifocal breast cancer in women ≤35 years old

Cancer

Volumn 110, Issue 7, 2007, Pages 1445-1450

  Litton, Jennifer K ^a   Eralp, Yesim ^b   Gonzalez Angulo, Ana M ^a   Broglio, Kristine ^a   Uyei, Anne ^a   Hortobagyi, Gabriel N ^a   Arun, Banu ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Age; Breast carcinoma; Multifocal disease; Survival

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; ONSET AGE; OUTCOMES RESEARCH; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS;

ADOLESCENT; ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 34648822741     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22928     Document Type: Article

References (38)

1. Ries L, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review 1975-2003. Bethesda, MD: National Cancer Institute; 2005.
2. Gonzalez-Angulo AM, Broglio K, Kau S, et al. Women age <35 years with primary breast carcinoma. Cancer. 2005;103:2466-2472.
3. Klauber-DeMore N. Tumor biology of breast cancer in young women. Breast Dis. 2005-2006;23:9-15.
4. Xiong Q, Valero V, Kau V, et al. Female patients with breast carcinoma age 30 years and younger have a poor prognosis. Cancer. 2001;92:2523-2528.
5. Sant M, Capocaccia R, Verdecchia A, et al. The Eurocare Working Group, survival of women with breast cancer in Europe: variation with age, year of diagnosis and country. Int J Cancer. 1998;77:679-683.
6. Chung M, Chang HR, Bland KI, Wanebo HJ. Younger women with breast carcinoma have a poorer prognosis than older women. Cancer. 1996;77:97-103.
7. Tai P, Cserni G, Van De Steene J, et al. Modeling the effect of age in T1-2 breast cancer using the SEER database. BMC Cancer. 2005;5:130.
8. Zhou P, Gautam S, Recht A. Factors affecting outcome for young women with early stage invasive breast cancer treated with breast-conserving therapy. Breast Cancer Res Treat. 2007;101:51-57.
9. Zhou P, Recht A. Young age and outcome for women with early stage invasive breast carcinoma. Cancer. 2004;101:1264-1274.
10. Adami HO, Malker B, Holmberg L, Persson I, Stone B. The relation between survival and age at diagnosis in breast cancer. N Engl J Med. 1986;315:559-63.
11. Nixon AJ, Neuberg D, Hayes DF, et al. Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol. 1994;12:888-894.
12. Winchester DP, Osteen RT, Menck HR. The National Cancer Data Base report on breast carcinoma characteristics and outcome in relation to age. Cancer. 1996;78:1838-1843.
13. Yildirim E, Dalgic T, Berberoglu U. Prognostic significance of young age in breast cancer. J Surg Oncol. 2000;74:267-272.
14. Maggard MA, O'Connell JB, Lane KE, Liu JH, Etzioni DA, Ko CY. Do young breast cancer patients have worse outcomes? J Surg Res. 2003;113:109-113.
15. Sidoni A, Cavaliere A, Belleza G, Scheibel M, Bucciarelli E. Breast cancer in young women: clinicopathological features and biological specificity. Breast 2003;12:247-250.
16. Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinomas occurring in young women (<35 years) are different. Br J Cancer. 1996;74:1796-1800.
17. Curigliano G, Rigo R, Colleoni M, et al. Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. Clin Breast Cancer. 2004;5:125-130.
18. Dubsky P, Grant MF, Taucher S, et al. Young age as an independent adverse prognostic factor in premenopausal women with breast cancer. Clin Breast Cancer. 2002;3:65-72.
19. Holland R, Veling SH, Mravunac M, Hendricks JH. Histologic multifocality of Tis, T1-2 breast carcinomas: implications for clinical trials of breast conserving surgery. Cancer 1985;56:979-990.
20. Wilkinson LS, Given-Wilson R, Hall T, Potts H, Sharma AK, Smith E. Increasing the diagnosis of multifocal primary breast cancer by the use of bilateral whole-breast ultrasound. Clin Radiol. 2005;60:573-578.
21. Chen AM, Meric-Bernstam F, Hunt KK, et al. Breast conservation after neoadjuvant chemotherapy. Cancer 2005;103:689-695.
22. Chua B, Ung O, Taylor R, Boyages J. Frequency and predictors of axillary lymph node metastases in invasive breast cancer. ANZ J Surg. 2001;71:723-728.
23. Egan R. Multicentric breast carcinomas: clinical-radiographic-pathologic whole organ studies and 10-year survival. Cancer. 1982;49:1123-1130.
24. Andea AA, Wallis T, Newman LA, Bouwman D, Dey J, Visscher DW. Pathologic analysis of tumor size and lymph node status in multifocal/multicentric breast carcinoma. Cancer. 2002;94:1383-1390.
25. Coombs NJ, Boyages J. Multifocal and multicentric breast cancer: does each focus matter? J Clin Oncol. 2005;23:7497-7502.
26. Andea AA, Bouwman D, Wallis T, Visscher DW. Correlation of tumor volume and surface area with lymoh node status in patients with multifocal/multicentric breast carcinoma. Cancer. 2004;100:20-27.
27. American Joint Commission on Cancer: Breast AJCC Cancer Staging Manual. 5th ed. Philadelphia: Lippincott-Raven; 1997:127-133.
28. Veronesi U, Bonadonna G, Zurrida S, et al. Conservation surgery after primary chemotherapy in large carcinomas of the breast. Ann Surg. 1995;222:612-618.
29. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol. 2001;19:4224-4237.
30. The World Health Organization histological typing of breast tumors, 2nd ed. Am J Clin Pathol. 1982;78:806-816.
31. Black M, Speer F. Nuclear structure in cancer tissue. Surg Gynecol Obstet. 1982;105:97-102.
32. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783-792.
33. Brinton LA, Darling JR, Liff JM, et al. Oral contraceptives and breast cancer risk among younger women. J Natl Cancer Inst. 1995;87:827-835.
34. White E, Malone KE, Weiss NS, Darling JR. Breast cancer among young US women in relation to oral contraceptive use. J Natl Cancer Inst. 1994;86:505-514.
35. Chen WY, Manson JE, Hankinson SE, et al. Unopposed estrogen therapy and the risk of invasive cancer. Arch Intern Med. 2006;166:1027-1032.
36. Vicini FA, Kestin LL, Goldstein NS, et al. Impact of young age on outcome in patients with ductal carcinoma-in-situ treated with breast-conserving therapy. J Clin Oncol. 2000;18:296.
37. Goldstein NS, Vicini FA, Kestin LL, Thomas M. Differences in the pathologic features of ductal carcinoma in situ of the breast based on patient age. Cancer 2000;88:2553-2560.
38. Jhingran A, Kim JS, Buchholz TA, et al. Age as a predictor of outcome for women with DCIS treated with breast-conserving surgery and radiation: the University of Texas M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys. 2002;54:804-809.